Drugs / TCR-like CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05963100 | Aug 2023 → May 2026 overdue | — | Zhongda Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR-like CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05963100 ↗ |
| Modality | Cell therapy | “TCR-like CAR-T” NCT05963100 ↗ |
| Route | Intravenous | “intravenous drip of TCR-like CAR-T with indicated doses” NCT05963100 ↗ |
| Target | MSLN | “Clinical Study of TCR-like CAR-T Cell Targeted MSLN in the Treatment of Ovarian Cancer” NCT05963100 ↗ |